| MannKind is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Co.'s primary product, Afrezza (insulin human) Inhalation Powder, is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Co. collaborates with United Therapeutics to develop an inhaled formulation of treprostinil known as Tyvaso DPI. We show 25 historical shares outstanding datapoints in our MNKD shares outstanding history coverage, used to compute MNKD market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MNKD market cap history over the course of time is important for investors
interested in comparing MNKD's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MNKD versus a peer is one thing; comparing
MNKD market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MNKD can fluctuate over the course of history.
With this page we aim to empower investors researching MNKD by allowing them to research the MNKD market cap history.